Pediatric Chronic Nonbacterial Osteomyelitis

Simple item page
dc.contributor.authorBorzutzky, Arturo
dc.contributor.authorStern, Sara
dc.contributor.authorReiff, Andreas
dc.contributor.authorZurakowski, David
dc.contributor.authorSteinberg, Evan A.
dc.contributor.authorDedeoglu, Fatma
dc.contributor.authorSundel, Robert P.
dc.date.accessioned2024-01-10T12:41:18Z
dc.date.available2024-01-10T12:41:18Z
dc.date.issued2012
dc.description.abstractBACKGROUND AND OBJECTIVES: Little information is available concerning the natural history and optimal treatment of chronic non-bacterial osteomyelitis (CNO). We conducted a retrospective review to assess the clinical characteristics and treatment responses of a large cohort of pediatric CNO patients.
dc.description.abstractMETHODS: Children diagnosed with CNO at 3 tertiary care centers in the United States between 1985 and 2009 were identified. Their charts were reviewed, and clinical, laboratory, histopathologic, and radiologic data were extracted.
dc.description.abstractRESULTS: Seventy children with CNO (67% female patients) were identified. Median age at onset was 9.6 years (range 3-17), and median follow-up was 1.8 years (range 0-13). Half of the patients had comorbid autoimmune diseases, and 49% had a family history of autoimmunity. Patients with comorbid autoimmune diseases had more bone lesions (P < .001), higher erythrocyte sedimentation rate (P < .05), and higher use of second line therapy (P = .02). Treatment response to nonsteroidal antiinflammatory drugs (NSAIDs), sulfasalazine, methotrexate, tumor necrosis factor alpha inhibitors, and corticosteroids was evaluated. The only significant predictor of a positive treatment response was the agent used (P < .0001). Estimated probability of response was 57% for NSAIDs, 66% for sulfasalazine, 91% for methotrexate, 91% for tumor necrosis factor a inhibitors, and 95% for corticosteroids.
dc.description.abstractCONCLUSIONS: In a US cohort of 70 children with CNO, coexisting autoimmunity was a risk factor for multifocal involvement and treatment with immunosuppressive agents. Disease-modifying antirheumatic drugs and biologics were more likely to lead to clinical improvement than NSAIDs. Pediatrics 2012;130:e1190-e1197
dc.description.funderPfizer
dc.description.funderAbbott
dc.fechaingreso.objetodigital2024-05-14
dc.format.extent8 páginas
dc.fuente.origenWOS
dc.identifier.doi10.1542/peds.2011-3788
dc.identifier.eissn1098-4275
dc.identifier.issn0031-4005
dc.identifier.pubmedidMEDLINE:23071213
dc.identifier.urihttps://doi.org/10.1542/peds.2011-3788
dc.identifier.urihttps://repositorio.uc.cl/handle/11534/77402
dc.identifier.wosidWOS:000310505900017
dc.information.autorucMedicina;Borzutzky A ;S/I;5897
dc.issue.numero5
dc.language.isoen
dc.nota.accesoSin adjunto
dc.publisherAMER ACAD PEDIATRICS
dc.revistaPEDIATRICS
dc.rightsregistro bibliográfico
dc.subjectchronic nonbacterial osteomyelitis
dc.subjectchronic recurrent multifocal osteomyelitis
dc.subjectosteomyelitis
dc.subjectautoimmunity
dc.subjectRECURRENT MULTIFOCAL OSTEOMYELITIS
dc.subjectDIFFUSE SCLEROSING OSTEOMYELITIS
dc.subjectSAPHO-SYNDROME
dc.subjectPAMIDRONATE TREATMENT
dc.subjectSUSTAINED REMISSION
dc.subjectFOLLOW-UP
dc.subjectTHERAPY
dc.subjectALPHA
dc.subjectCHILDREN
dc.subjectOSTEITIS
dc.subject.ods03 Good Health and Well-being
dc.subject.odspa03 Salud y bienestar
dc.titlePediatric Chronic Nonbacterial Osteomyelitis
dc.typeartículo
dc.volumen130
sipa.codpersvinculados5897
sipa.indexWOS
sipa.indexScopus
sipa.trazabilidadCarga SIPA;09-01-2024
Files
Original bundle
Now showing 1 - 1 of 1
Thumbnail Image
Name:
Pediatric Chronic Nonbacterial Osteomyelitis.pdf
Size:
101.4 KB
Format:
Adobe Portable Document Format
Description:
Download
Collections
Artículos de revistas